Unanswered questions in contraceptive management: What do the experts do?

Journal of Family Planning and Reproductive Health Care

Volumn 30, Issue 4, 2004, Pages 229-235

  Brooker, Catherine ^a   Guillebaud, John ^b  

^a University College London ^*

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYPROTERONE ACETATE; DESOGESTREL; ESTROGEN; ETONOGESTREL; GESTAGEN; LEVONELLE; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT;

ARTICLE; BODY MASS; BREAST CANCER; CEREBROVASCULAR ACCIDENT; DRUG PACKAGING; ERYTHEMA NODOSUM; FETOTOXICITY; HORMONAL CONTRACEPTION; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; MIGRAINE; NATIONAL HEALTH SERVICE; PACKAGING; PHYSICIAN; QUESTIONNAIRE; REPRODUCTIVE HEALTH; TROPHOBLASTIC DISEASE;

CONTRACEPTION; CONTRACEPTIVES, POSTCOITAL; FEMALE; GREAT BRITAIN; HEALTH CARE SURVEYS; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PROGESTINS; QUESTIONNAIRES; REPRODUCTIVE MEDICINE; STATE MEDICINE;

EID: 7044249207     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1783/0000000042177063     Document Type: Article

References (47)

1. Guillebaud J. Appendix A. Contraception - Your Questions Answered (3rd, 4th edns). Edinburgh, UK: Churchill Livingstone, 1999, 2004.
2. Guillebaud J. Contraception Today (5th edn). London, UK: Martin Dunitz, 2004.
3. Phillips B, Ball C, Sackett D, et al. Levels of Evidence and Grades of Recommendations. Oxford Centre for Evidence-based Medicine Levels of Evidence (May 2001). http://www.cebm.net/levels _of_evidence.asp. November 1998.
4. UK Data Sheet Compendium, http://www.emc.medicines.org.uk [Accessed April 2004].
5. Vessey MP, Villard-Mackintosh L, Yeates D. Effectiveness of progestogen-only oral contraceptives. Br J Fam Plann 1990; 16: 79.
6. Kovacs G, Hendricks J, Summerbell D, et al. A pre-coital pill? A preliminary in vitro study. Br J Fam Plann 2000; 26: 165-166.
7. Guillebaud J. Progestogen-only pills (POPs) and body weight. J Fam Plann Reprod Health Care 2001; 27: 239.
8. Kubba A, Sanfilippo J, Hampton N. Contraception and Office Gynaecology. London, UK: W B Saunders, 1999.
9. Hatcher RA, Trussell J, Stewart F, et al. (eds). Contraceptive Technology. New York, NY: Ardent Media Inc., 1998.
10. Glasier A, Gebbie A. Handbook of Family Planning and Reproductive Health Care (4th edn). London, UK: Churchill Livingstone, 2000.
11. de Souza A, Brechin S, Penney G. The members' enquiry service: frequently asked questions. J Fam Plann Reprod Health Care 2003; 29(3): 160-161.
12. Brechin S, Penney G, de Souza A. New Product Review (April 2003). Desogestrel-only pill (Cerazette). J Fam Plann Reprod Health Care 2003; 29(3): 162-164.
13. Glasier A. Emergency postcoital contraception. N Engl J Med 1997; 337: 1058-1064.
14. Task Force on Postovulatory Methods of Fertility Regulation. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet 1998; 352: 428-433.
15. Schering website. http://www.schering.co.uk/content/health_pros (updated November 2003).
16. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. FPPRHC Guidance. Emergency contraception. J Fam Plann Reprod Health Care 2003; 29(2): 9-16.
17. von Hertzen H, Piaggio G, Ding J, et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet 2002; 360: 1803-1810.
18. Wilcox AJ, Dunson D, Baird D. The timing of the "fertile window" in the menstrual cycle: day specific estimate from a prospective study. BMJ 2000; 321: 1259-1262.
19. Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs 2002; 16: 263-272.
20. Bounds W, Guillebaud J. Observational series on women using the contraceptive Mirena concurrently with anti-epileptic and other enzyme-inducing drugs. J Fam Plann Reprod Health Care 2002; 28: 78-80.
21. Ellison J, Thomson, AJ, Greer IA, et al. Drug points: apparent interaction between warfarin and levonorgestrel used for emergency contraception. BMJ 2000; 321: 1382.
22. Ratz AE, von Moos M, Drewe J. St John's Wort: a pharmaceutical with potentially dangerous interactions. Schweiz Rundsch Med Prax 2001; 90: 843-849.
23. Varila E, Wahlstrom T, Rauramo I. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril 2001; 76: 969-975.
24. Hubacher D, Grimes DA. Non-contraceptive health benefits of intrauterine devices: a systematic review. Obstet Gynaecol Surv 2002; 57: 120-128.
25. Newton J. Tacchi D. Long term use of copper intrauterine devices. A statement from the Medical Advisory Committee of the Family Planning Association and the National Association of Family Planning Doctors. Lancet 1990; 335: 1322-1323.
26. Sivin S, el Mahgoub S, McCarthy T, et al. Long term contraception with levonorgestrel 20mcg/day (Lng 20) and CopperT 380Ag intrauterine devices: a 5 year randomized study. Contraception 1990; 42: 361-378.
27. Sivin I, Stern J, Coutinho E, et al. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20mcg/day (Lng 20) and CopperT 380Ag IUDS. Contraception 1991; 44: 473-480.
28. Kaunitz AM. Menstruation: choosing whether ... and when. Contraception 2000; 62: 277-284.
29. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. FPPRHC Guidance (October 2003). First prescription of combined oral contraception. J Fam Plann Reprod Health Care 2003; 29(4): 209-223.
30. Committee for the Safety of Medicines/Medicines Control Agency (CSM/MCA). Cyproterone acetate (Dianette): risk of venous thromboembolism. Curr Probl Pharmacovigilance 2002; 28: 9-10. http://www.mca.gov.uk.
31. Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 2001; 358: 1427-1429.
32. Rabe T, Feldman K, Heinemann L, et al. Cyproterone acetate: is it hepato- or genotoxic? Drug Saf 1996; 14: 25-38.
33. The Collaborative MILTS Project Team. Oral contraceptives and liver cancer - results of the Multicentre International Liver Tumour Study. Contraception 1997; 56: 275-284.
34. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. FPPRHC Guidance (July 2003). Contraceptive choices for women with inflammatory bowel disease. J Fam Plann Reprod Health Care 2003; 29(3): 127-135.
35. Stone M, Bagshawe KD. An analysis of the influences of maternal age, gestational age, contraceptive method and the mode of primary treatment of patients with hydatidiform moles on the incidence of subsequent chemotherapy. Br J Obstet Gynaecol 1979; 86: 782-792.
36. Gerulath AH, Ehlen TG, Bessetle P, et al. Gestational trophoblastic disease. J Obstet Gynaecol Can 2002; 24: 434-446.
37. Tzourio C, Tehindrazanarivelo A, Igle'sias S, et al. Case-control of migraine and risk of ischaemic stroke in young women. BMJ 1995; 310: 830-833.
38. Carolei A, Marini C, De Matteis G and the Italian National Research Study Council Group on Stroke in the Young. History of migraine and risk of cerebral ischaemia in young adults. Lancet 1996; 347: 1503-1506.
39. United States Department of Health and Human Services. The Health Benefits of Smoking Cessation: A Report of the Surgeon General. DHHS Publication No. (CDC) 90-8416. Rockville, MD: United States Public Health Service, Office on Smoking and Health, 1990.
40. Kawachi CI, Colditz GA, Stampfer MJ, et al. Smoking cessation in relation to total morbidity rates in women: a prospective cohort study. Ann Intern Med 1993; 119: 992-1000.
41. Marchbanks P, McDonald J, Wilson H, et al. Oral contraceptives and their risk of breast cancer. N Engl J Med 2002; 346: 2025-2032.
42. Grabrick D, Hartmann L, Cerhan J, et al. Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA 2000; 284: 1791-1798.
43. Friedenson B. A current perspective of genetic testing for breast and ovarian cancer: the oral contraceptive decision (Review). MedGenMed 2001; 3(4). http://www.medscape.com/viewarticle/ 408191 [Accessed 5 January 2004].
44. Narod SA, Dube MP, Klijn J. Oral contraceptives and the risk of breast cancer in BRCA 1 and BRCA 2 mutation carriers. J Natl Cancer Inst 2002; 94: 1773-1770.
45. World Health Organization (WHO). Medical Eligibility Criteria for Contraceptive Use. Geneva, Switzerland: WHO, 2000.
46. World Health Organization (WHO). Selected Practice Recommendations for Contraceptive Use. Geneva, Switzerland: WHO, 2002.
47. Glasier A, Brechin S, Raine R, et al. A consensus process to adapt the World Health Organization Selected Practice Recommendations for UK use. Contraception 2000; 68: 327-333.